Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Direct Cost Analysis About The Three Chelators For The Treatment Of Thalassemia Patients With Chronic Iron Overload: An Italian Perspective From The MIOT Network

Alessia Pepe, MD, PhD, Antonella Meloni, PhD, Giuseppe Rossi, MSc, Antonella Carollo, MD, Vincenzo Santamaria, MD, Augusto Scaccetti, MD, Gaetano Roccamo, MD, Aurelio Maggio, MD, Massimo Lombardi, MD

Blood (2013) 122 (21): 5605.

https://doi.org/10.1182/blood.V122.21.5605.5605

Published: 2013

Journal Articles

Comparison Of Two Combination Iron Chelation Regimens, Deferiprone and Deferasirox Versus Deferiprone and Deferoxamine, In Pediatric Patients With β-Thalassemia Major

Mohsen Saleh Elalfy, Yasser Wali, MD, FRCPCH, (UK), S Tony, Ahmed Samir, Amira Adly

Blood (2013) 122 (21): 559.

https://doi.org/10.1182/blood.V122.21.559.559

Published: 2013

Journal Articles

Safety and Efficacy of High Dose Intravenous Desferoxamine for Reduction of Iron Overload Due to Chronic Transfusion in Sickle Cell Patients.

Ram Kalpatthi, MD, Brittany Peters, David Holloman, Elizabeth Rackoffe, Deborah Disco, Sherron Jackson, Miguel Abboud, MD

Blood (2008) 112 (11): 1430.

https://doi.org/10.1182/blood.V112.11.1430.1430

Published: 2008

Journal Articles

Cumulative Efficacy and Safety of 5-Year Deferasirox (Exjade ® ) Treatment in Pediatric Patients with Thalassemia Major: A Phase II Multicenter Prospective Trial

Antonio Piga, Kamila Kebaili, Renzo Galanello, Valentine Jehl, Corinne Rebischung, Henry Maseruka, Lisa Rojkjaer, Gian Luca Forni

Blood (2008) 112 (11): 5413.

https://doi.org/10.1182/blood.V112.11.5413.5413

Published: 2008

Journal Articles

Once-Daily Treatment with the Oral Iron Chelator ICL670 (Exjade®): Results of a Phase II Study in Pediatric Patients with β-Thalassemia Major.

Antonio Piga, MD, Renzo Galanello, MD, Maria Loreta Foschini, MD, Antonella Zappu, MD, Elena Bordone, MD, Filomena Longo, MD, Gian-Luca Forni, MD, Antonella Lavagetto, MD, Yves Bertrand, MD, Henry Maseruka, PhD, Nicola Latham, MSc, Daniele Alberti, MD

Blood (2004) 104 (11): 3614.

https://doi.org/10.1182/blood.V104.11.3614.3614

Published: 2004

NARROW

Direct Cost Analysis About The Three Chelators For The Treatment Of Thalassemia Patients With Chronic Iron Overload: An Italian Perspective From The MIOT Network

Comparison Of Two Combination Iron Chelation Regimens, Deferiprone and Deferasirox Versus Deferiprone and Deferoxamine, In Pediatric Patients With β-Thalassemia Major

Safety and Efficacy of High Dose Intravenous Desferoxamine for Reduction of Iron Overload Due to Chronic Transfusion in Sickle Cell Patients.

Cumulative Efficacy and Safety of 5-Year Deferasirox (Exjade ® ) Treatment in Pediatric Patients with Thalassemia Major: A Phase II Multicenter Prospective Trial

Once-Daily Treatment with the Oral Iron Chelator ICL670 (Exjade®): Results of a Phase II Study in Pediatric Patients with β-Thalassemia Major.

Email alerts

ASH Publications

American Society of Hematology

Direct Cost Analysis About The Three Chelators For The Treatment Of Thalassemia Patients With Chronic Iron Overload: An Italian Perspective From The MIOT Network

Comparison Of Two Combination Iron Chelation Regimens, Deferiprone and Deferasirox Versus Deferiprone and Deferoxamine, In Pediatric Patients With β-Thalassemia Major

Safety and Efficacy of High Dose Intravenous Desferoxamine for Reduction of Iron Overload Due to Chronic Transfusion in Sickle Cell Patients.

Cumulative Efficacy and Safety of 5-Year Deferasirox (Exjade ® ) Treatment in Pediatric Patients with Thalassemia Major: A Phase II Multicenter Prospective Trial

Once-Daily Treatment with the Oral Iron Chelator ICL670 (Exjade®): Results of a Phase II Study in Pediatric Patients with β-Thalassemia Major.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only